Nordisk | Jotup

e-therapeutics: Fundraise of £13.5 million

Retrieved on:

Friday, September 30, 2022

Ali Mortazavi, Chief Executive Officer of e-therapeutics, commented:

Key Points:

Ali Mortazavi, Chief Executive Officer of e-therapeutics, commented:
"I am pleased to announce the fundraise of 13.5 million and excited by the prospect of being able to accelerate the development of our in-house RNAi pipeline through enhanced investment in our therapeutic programmes, hepatocyte datasets and computational capabilities.
This successful fundraise underlines ETX's position at the intersection of computational approaches to drug discovery and genetic medicine, using RNA interference as our drug modality of choice.
We are grateful for the support of our shareholders and look forward to delivering value from our platform technologies."
The Company generates, prioritises and tests millions of hypotheses in silico to identify better therapeutic targets with higher confidence.

e-therapeutics: Fundraise of £13.5 million

Retrieved on:

Friday, September 30, 2022

Ali Mortazavi, Chief Executive Officer of e-therapeutics, commented:

Key Points:

Ali Mortazavi, Chief Executive Officer of e-therapeutics, commented:
"I am pleased to announce the fundraise of 13.5 million and excited by the prospect of being able to accelerate the development of our in-house RNAi pipeline through enhanced investment in our therapeutic programmes, hepatocyte datasets and computational capabilities.
This successful fundraise underlines ETX's position at the intersection of computational approaches to drug discovery and genetic medicine, using RNA interference as our drug modality of choice.
We are grateful for the support of our shareholders and look forward to delivering value from our platform technologies."
The Company generates, prioritises and tests millions of hypotheses in silico to identify better therapeutic targets with higher confidence.

Nordisk Film Adopts Qlik Cloud Analytics for Operational Efficiencies and Reduced Costs

Retrieved on:

Wednesday, August 10, 2022

Cloud, Computer, Comment, Intelligence, Name, GLOBE, Senior, AI, EMEA, Memory, Knowledge, Life, Qlik, Egmont, Azure AD Connect, Gaps, Maintenance, Nordisk Film, Solution, Time, PlayStation, Adoption, Video game console, Nordic, Nordisk

PHILADELPHIA, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Qlik today announced Nordisk Film, the Nordic region's leading creator and distributor of films, has adopted Qlik Cloud Analytics to realize operational efficiencies, reduce costs associated with data preparation and analysis, and ultimately expand data-decision making throughout the organization.

Key Points:

PHILADELPHIA, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Qlik today announced Nordisk Film, the Nordic region's leading creator and distributor of films, has adopted Qlik Cloud Analytics to realize operational efficiencies, reduce costs associated with data preparation and analysis, and ultimately expand data-decision making throughout the organization.
Nordisk Film was also looking to increase collaboration and streamline its different computer systems and data warehouses into a single cloud platform.
Nordisk Film chose to move to Qlik Cloud for importing, clearing and analyzing data in order to make more informed business decisions while leveraging Qlik Sense SaaS.
And Qlik being easy-to-learn and applicable to many different business areas has helped Nordisk Film expand analytics adoption across the business.

Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition

Retrieved on:

Tuesday, December 28, 2021

Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed.

Key Points:

Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed.
Following the expiration of Novo Nordisks cash tender offer for Dicerna, Novo Nordisk has today acquired all outstanding shares of common stock of Dicerna at a price of USD 38.25 per share in cash, without interest and less any applicable tax withholding.
At the completion of the merger, Dicerna became a wholly owned subsidiary of Novo Nordisk.
Novo Nordisk employs about 47,000 people in 80 countries and markets its products in around 170 countries.

Team Novo Nordisk Announces New Partnership with the micro mobility safety app Busby

Retrieved on:

Tuesday, August 3, 2021

Novo Nordisk, Life sciences, Industry economics), Companies, Nordisk

ATLANTA, Aug. 3, 2021 /PRNewswire-PRWeb/ --Team Novo Nordisk, the world's first all-diabetes professional cycling team, today announced a new partnership with Busby, the micro mobility safety app.

Key Points:

ATLANTA, Aug. 3, 2021 /PRNewswire-PRWeb/ --Team Novo Nordisk, the world's first all-diabetes professional cycling team, today announced a new partnership with Busby, the micro mobility safety app.
"Busby is the best cycling app for road safety and we are excited to announce this collaboration and join them in the mission to help improve road safety through technology," said Phil Southerland, CEO and co-founder of Team Novo Nordisk.
James Duffy, Co-Founder and Commercial Director of Busby, said of the new partnership: 'Team Novo Nordisk's mission over and above riding bikes is hugely inspiring.
Team Novo Nordisk is a global all-diabetes sports team of cyclists spearheaded by the world's first all-diabetes professional cycling team.

Novo Holdings Leads US$ 118M Series C Investment in Genomatica

Retrieved on:

Tuesday, July 27, 2021

Life sciences, Novo Holdings A/S, Articles, Novo Nordisk, Economy of Denmark, Biobased economy, Nordisk

COPENHAGEN, Denmark and SAN DIEGO, July 27, 2021 /PRNewswire/ -- Novo Holdings, a leading international life science investor, today announces that it has led the US$ 118M Series C financing in new portfolio company Genomatica, which harnesses biology to remake everyday products and materials with a reduced environmental impact. The funding will be used to accelerate the global commercialization and expansion of Genomatica's sustainable materials, with the potential to reduce greenhouse gas emissions by 100 million tons per year.

Key Points:

Anders Bendsen Spohr, Senior Partner at Novo Holdings, said:"Novo Holdings is committed to support the development of sustainable and renewable materials.
"We are very pleased to welcome Novo Holdings, a world class investor which has long been a champion of the bioeconomy, to Genomatica.
Leading a widespread transition to sustainable materials is what drives us at Genomatica," said Christophe Schilling, Chief Executive Officer of Genomatica.
Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation.

Novo Holdings Leads US$ 118M Series C Investment in Genomatica

Retrieved on:

Tuesday, July 27, 2021

Life sciences, Novo Holdings A/S, Articles, Novo Nordisk, Economy of Denmark, Biobased economy, Nordisk

Anders Bendsen Spohr, Senior Partner at Novo Holdings, said:"Novo Holdings is committed to support the development of sustainable and renewable materials.

Key Points:

Anders Bendsen Spohr, Senior Partner at Novo Holdings, said:"Novo Holdings is committed to support the development of sustainable and renewable materials.
"We are very pleased to welcome Novo Holdings, a world class investor which has long been a champion of the bioeconomy, to Genomatica.
Leading a widespread transition to sustainable materials is what drives us at Genomatica," said Christophe Schilling, Chief Executive Officer of Genomatica.
Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation.

Team Novo Nordisk partner with Hyperice, leader in recovery and movement enhancement

Retrieved on:

Thursday, July 8, 2021

Team Novo Nordisk, CBS Sports, Novo Nordisk, TNN Motor Sports, Nordisk, Life sciences, Industry economics), Companies

"The new addition of Hyperice to the TNN Sports Performance and Recovery Program provides an exciting set of new tools," said Rafael Castol, TNN Chief Medical Officer.

Key Points:

"The new addition of Hyperice to the TNN Sports Performance and Recovery Program provides an exciting set of new tools," said Rafael Castol, TNN Chief Medical Officer.
Hyperice is the leader in recovery and movement enhancement technology.
"We are excited about our partnership with Team Novo Nordisk," said Shawn Beitelspacher, VP Endurance and Specialty Retail at Hyperice.
As the global recovery technology leader, specializing in vibration, percussion and thermal technology, Hyperice is used by the most elite athletes, professional sports leagues and teams to optimize player performance.

Amalgam Rx™ and Novo Nordisk® Plan Global Expansion

Retrieved on:

Wednesday, June 16, 2021

Health, Medical devices, Technology, Mobile, Wireless, Software, Pharmaceutical, Biotechnology, Life sciences, Insulin, Novo Nordisk, Clinical medicine, Health care, Nordisk

Amalgam Rx, Inc., the leader in connecting healthcare providers and life sciences companies through a SaaS-enabled digital marketplace and product platform, is announcing global expansion of its insulin titration solution with Novo Nordisk.

Key Points:

Amalgam Rx, Inc., the leader in connecting healthcare providers and life sciences companies through a SaaS-enabled digital marketplace and product platform, is announcing global expansion of its insulin titration solution with Novo Nordisk.
Now, with Amalgams recently received CE Mark for iSage Rx and Dose Check, Novo Nordisk is planning a global expansion.
View the full release here: https://www.businesswire.com/news/home/20210616005522/en/
Amalgam Rx and Novo Nordisk Plan Global Expansion (Graphic: Business Wire)
Were excited about expanding our partnership with Amalgam and bolstering our efforts to facilitate evidence-based insulin initiation and titration in conjunction with our strong insulin portfolio, said Anne Dorothee Vonmoos, Novo Nordisks senior director, head of commercial planning in io-so commercial affairs and strategy.
We look forward to expanding the Dose Check program and supporting Novo Nordisk on a global basis, said Ryan Sysko, chief executive officer and founder of Amalgam Rx.

Novo Nordisk to present research across diabetes and obesity portfolio at the 81st Annual American Diabetes Association Scientific Sessions

Retrieved on:

Wednesday, June 16, 2021

Novo Nordisk, Life sciences, Nordisk, Industry economics), Companies

PLAINSBORO, N.J., June 16, 2021 /PRNewswire/ -- Novo Nordisk announced that new data from more than 30 abstracts will be presented from the company's approved and investigational medicines highlighting its broad diabetes and obesity portfolio at the upcoming 81st Annual Scientific Sessions of the American Diabetes Association (ADA).

Key Points:

PLAINSBORO, N.J., June 16, 2021 /PRNewswire/ -- Novo Nordisk announced that new data from more than 30 abstracts will be presented from the company's approved and investigational medicines highlighting its broad diabetes and obesity portfolio at the upcoming 81st Annual Scientific Sessions of the American Diabetes Association (ADA).
This press release contains forward-looking statements about investigational products currently in development by Novo Nordisk.
Novo Nordisk is a global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for 95 years.
With U.S. headquarters in New Jersey and production and research facilities in six states, Novo Nordisk employs nearly 6,000 people throughout the country.